Dr Lal PathLabs Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹31,762 Cr
- Book Value
- ₹150
- Stock P/E
- 56.5
- Dividend Yield
- 0.74%
- ROE
- 22.3%
- ROCE
- 28.0%
- PEG Ratio
- 4.58
- EV/EBITDA
- 32.9
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Dr Lal PathLabs share price today
Dr Lal PathLabs (NSE: DRLALPATH) is north India’s diagnostics utility: a hub-and-spoke network where thousands of collection points feed samples into regional labs and a national reference lab, spreading fixed costs across volumes no standalone lab can match. The brand — built over decades of doctor trust — is the demand engine; the network is the margin engine (29% operating margins, 28% ROCE, near-zero debt).
The sector’s story since 2021 was the online price war (Tata 1mg, PharmEasy discounting tests to acquire users). It burned everyone’s growth optics — and it is cooling, with profit growth re-accelerating into the thirties over three years. At 56.5×, our universe tags it wait: quality proven, price full.
Network economics in a trust business
Diagnostics rewards density: more collection points per city means faster logistics, fresher samples, better doctor service — and each incremental test rides near-zero marginal cost. Dr Lal’s north-India density is its fortress; the east and central expansions replicate the playbook city by city. Swasthfit bundles (preventive packages) premiumise the mix, and the reference lab does the esoteric, high-value tests smaller chains send out — often to Dr Lal itself.
Watch-items: online-discounter behaviour (the cooled war can reheat), volume growth versus realisation per test, southern-market competition (Metropolis’s home turf), and acquisition discipline as consolidation resumes.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹31,762 Cr |
| P/E (TTM) | 56.5 |
| EV/EBITDA | 32.9 |
| Operating margin | 29.0% |
| ROE / ROCE | 22.3% / 28.0% |
| Debt to equity | 0.08 |
| Sales CAGR (5y) | 11.8% |
| Profit CAGR (5y) | 12.3% |
| Promoter holding | 53.2% |
| EPS (TTM) | ₹33.45 |
Dr Lal PathLabs share price target 2026 to 2030
EPS base ₹33.45 (TTM). Bear: the price war reignites — 8% growth, multiple at 32×. Base: volumes compound as pricing normalises — 13% growth at 44×. Bull: consolidation plus preventive-testing culture — 18% growth at 56×.
| Year | Bear (32×, +8%) | Base (44×, +13%) | Bull (56×, +18%) |
|---|---|---|---|
| 2026 | ₹1,155 | ₹1,665 | ₹2,210 |
| 2027 | ₹1,250 | ₹1,880 | ₹2,610 |
| 2028 | ₹1,350 | ₹2,125 | ₹3,080 |
| 2029 | ₹1,455 | ₹2,400 | ₹3,630 |
| 2030 | ₹1,575 | ₹2,710 | ₹4,285 |
From ₹1,889, the base case is ≈ +44% over four and a half years plus a 0.7% yield; the bear is −17%. Healthcare annuities deserve premium prices — the range below just declines to pay the peak of one.
Reasons to own Dr Lal PathLabs (at the right price)
- Hub-and-spoke density — the cost curve no standalone lab or online entrant matches.
- Doctor-trust brand: prescriptions still route most diagnostic volume.
- 29% margins and net cash through the industry’s worst price war.
- Preventive-testing culture (Swasthfit) is a structural mix upgrade.
- Fragmented industry: consolidation hands share to the network leaders.
The risks: online discounters can reignite pricing any quarter, south-India expansion fights an entrenched peer, and 56× assumes the war stays cool.
Should you buy at the current price?
The live buy range below is for members — where the network’s premium gets reasonable.
FAQ
What is the Dr Lal PathLabs share price target for 2030? Base case ≈ ₹2,710 (44× on 13% compounded growth), bear ≈ ₹1,575, bull ≈ ₹4,285. Arithmetic above.
Did online players kill diagnostics economics? They compressed prices for walk-in test bookings; doctor-prescribed and complex testing — the bulk of Dr Lal’s value — proved stickier. The war hurt optics more than the franchise.
What is the reference-lab advantage? Esoteric tests (genetics, specialised panels) need scale one national lab can justify — smaller labs outsource these, making Dr Lal a supplier to its own competitors.
When are Dr Lal PathLabs’ next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.